title: Effects of propofol and Intralipid on immune response and prostaglandin E2 production.
abstract: The present study evaluated the effects of propofol and its solvent Intralipid on the immune response and in vivo prostaglandin E2 production in patients during induction of anaesthesia and in healthy volunteers after Intralipid injection. Fifteen female patients (median age 48 years, ASA 1-2) scheduled for uterine dilatation and curettage were randomly assigned to two groups. In group 1 propofol (median dose 3.1 mg.kg-1) and in group 2 thiopentone (median dose 6.0 mg.kg-1) were injected intravenously over 60 s. Surgery was started after collection of the last blood sample. In the second part of this study, Intralipid 10% 0.3 ml.kg-1 was injected intravenously in eight healthy volunteers (four women and four men, median age 32 years) over 60 s. Plasma bicyclo-PGE2 concentrations increased during anaesthesia induction in both anaesthetic groups (p < 0.01). By contrast, no changes were seen in plasma bicyclo-PGE2 concentrations after Intralipid injection in volunteers. Lymphocyte proliferative responses to mitogens did not change during anaesthesia induction in patients. In volunteers, Intralipid injection caused a slight increase in T-cell percentages (p < 0.01) and unstimulated lymphocyte proliferative responses (p < 0.05), but it did not affect other lymphocyte subsets and immunoglobulin production. Intralipid and propofol were not found to be immunosuppressive at clinical doses used during anaesthesia induction.
authors.affiliation: Department of Anaesthesiology, University of Turku, Finland.
authors.forename: C O
authors.initials: CO
authors.lastname: Pirttikangas
authors.forename: M
authors.initials: M
authors.lastname: Salo
authors.forename: A
authors.initials: A
authors.lastname: Riutta
authors.forename: J
authors.initials: J
authors.lastname: Perttilä
authors.forename: O
authors.initials: O
authors.lastname: Peltola
authors.forename: O
authors.initials: O
authors.lastname: Kirvela
mesh_terms: D000328:Adult; D000771:Anesthesia, Intravenous; D000917:Antibody Formation / Q000187:drug effects; D004107:Dilatation and Curettage; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D004655:Emulsions; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects*; D007136:Immunoglobulins / Q000096:biosynthesis; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010743:Phospholipids; D015742:Propofol / Q000494:pharmacology*; D013024:Soybean Oil; D013874:Thiopental / Q000494:pharmacology
chemical_list: D004655:Emulsions; D005217:Fat Emulsions, Intravenous; D007136:Immunoglobulins; D010743:Phospholipids; C545823:soybean oil, phospholipid emulsion; C025088:11-deoxy-15-keto-13,14-dihydro-11 beta,16-cycloprostaglandin E2; D013024:Soybean Oil; D013874:Thiopental; D015232:Dinoprostone; D015742:Propofol